Loading...

APC anti-mouse CD62L Antibody

Pricing & Availability
Clone
MEL-14 (See other available formats)
Regulatory Status
RUO
Other Names
L-selectin, LECAM-1, Ly-22, LAM-1, MEL-14
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
MEL-14_APC_090707
C57BL/6 mouse splenocytes were stained with CD62L (clone MEL-14) APC (filled histogram) or rat IgG2a, κ APC isotype control (open histogram).
  • MEL-14_APC_090707
    C57BL/6 mouse splenocytes were stained with CD62L (clone MEL-14) APC (filled histogram) or rat IgG2a, κ APC isotype control (open histogram).
Compare all formats See APC spectral data
Cat # Size Price Quantity Check Availability Save
104411 25 µg 53€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
104412 100 µg 155€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD62L is a 74-95 kD glycoprotein also known as L-selectin, LECAM-1, Ly-22, LAM-1, and MEL-14. It is a member of the selectin family and is expressed on the majority of B and naïve T cells, a subset of memory T cells, monocytes, granulocytes, most thymocytes, and a subset of NK cells. CD62L is important in lymphocyte homing to high endothelial venules (HEV) in peripheral lymph nodes and leukocyte "rolling" on activated endothelium. CD62L also contributes to neutrophil emigration at inflammatory sites. CD62L is rapidly shed from lymphocytes and neutrophils upon cellular activation and the expression levels of CD62L (in conjunction with other markers) have been used to distinguish naïve, effector, and memory T cells. CD62L has been reported to interact with CD34, GlyCAM-1, and MAdCAM-1.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
C3H/eb mouse B lymphoma 38C-13
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with APC under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 106 cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Red Laser (633 nm)
Application Notes

Additional reported applications (for the relevant formats) include: immunoprecipitation1-3, complement-dependent cytotoxicity4, in vivo and in vitro blocking of adhesion1-3,5, and immunohistochemical staining of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections6. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. Nos. 104457-104462).

Application References
  1. Gallatin WM, et al. 1983. Nature 304:30. (IP, Block)
  2. Siegelman MH, et al. 1990. Cell 61:611. (IP, Block)
  3. Lewinsohn DM, et al. 1987. J. Immunol. 138:4313. (IP, Block)
  4. Iwabuchi K, et al. 1991. Immunobiology 182:161. (CMCD)
  5. Pizcueta P, et al. 1994. Am. J. Pathol. 145:461.
  6. Reichert RA, et al. 1986. J. Immunol. 136:3535. (IHC, FC)
  7. Olver S, et al. 2006. Cancer Res. 66:571.
  8. Fukushima A, et al. 2006. Invest. Ophthalmol. Vis. Sci. 47:657. PubMed
  9. Benson MJ, et al. 2007. J. Exp. Med. doi:10.1084/jem.20070719. (FC) PubMed
  10. Chappaz S, et al. 2007. Blood doi:10.1182/blood-2007-02-074245. (FC) PubMed
  11. Lee JW, et al. 2006. Nature Immunol. 8:181.
  12. Shigeta A, et al. 2008. Blood 112:4915 (FC) PubMed
  13. de Vries VC, et al. 2009. Am. J. Transplant. 9:2270 PubMed
Product Citations
  1. Cowan J, et al. 2013. J Exp Med. 210:675. PubMed
  2. Ender F, et al. 2017. PLoS One. 12(2):e0172446. PubMed
  3. Sun L, et al. 2021. Cancer Cell. 39:1361. PubMed
  4. Jayachandran R, et al. 2019. Immunity. 50:152. PubMed
  5. Luo J, et al. 2022. J Nanobiotechnology. 20:228. PubMed
  6. Qian Y, et al. 2021. Cell Reports. 36(8):109602. PubMed
  7. Chappaz S, et al. 2021. Cell Reports. 36(3):109430. PubMed
  8. Rezende R, et al. 2015. Nat Commun. 6: 8726. PubMed
  9. Wang J, et al. 2012. Blood. 120:1489. PubMed
  10. Martens R, et al. 2020. Nat Commun. 11:1114. PubMed
  11. Thi VAD, et al. 2019. Mol Cells. 42:869. PubMed
  12. Hirata Y et al. 2018. Cell stem cell. 22(3):445-453 . PubMed
  13. Shibata K, et al. 2022. Nat Commun. 13:6948. PubMed
  14. Li Q, et al. 2022. Cell Rep. 40:111308. PubMed
  15. Gabriely G, et al. 2021. iScience. 24:103347. PubMed
  16. Di Martile M, et al. 2020. J Immunother Cancer. 8:. PubMed
  17. Shapiro MR, et al. 2020. Front Immunol. 1.972222222. PubMed
  18. Ren S, et al. 2019. Oncol Rep. 41:1509. PubMed
  19. Baptista AP et al. 2019. Immunity. 50(5):1188-1201 . PubMed
  20. Kim CJ, et al. 2018. Immunity. 49:1034. PubMed
  21. Gilleron J et al. 2018. Cell reports. 25(12):3329-3341 . PubMed
  22. Wei H, et al. 2021. Malar J. 20:89. PubMed
  23. Duan Q, et al. 2021. Front Cell Dev Biol. 9:761193. PubMed
  24. Jiang W, et al. 2022. Front Immunol. 13:878832. PubMed
  25. Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
  26. Mirshahi F, et al. 2022. Cell Rep. 38:110454. PubMed
  27. Zhao Y, et al. 2021. J Biol Chem. 297:101166. PubMed
  28. Nagaoka M, et al. 2014. J Immunol. 193:2812. PubMed
  29. Bartleson JM, et al. 2020. Nat Immunol. 1384:21. PubMed
  30. Wiese A, et al. 2017. PLoS One. 10.1371/journal.pone.0184956. PubMed
  31. Roy S, et al. 2020. Sci Rep. 10:10992. PubMed
  32. Yoon Y, et al. 2021. Cancers (Basel). 13: . PubMed
  33. Zhou HF, et al. 2022. Front Pharmacol. 13:778755. PubMed
  34. Mitchell JE, et al. 2021. Cell Reports. 35(2):108966. PubMed
  35. Guo Z, et al. 2016. Nat Commun. 7:10307. PubMed
  36. Uchimura T et al. 2018. Immunity. 49(6):1049-1061 . PubMed
  37. Sasaki K, et al. 2019. Nat Commun. 10:3878. PubMed
  38. Li Y, et al. 2020. Nat Commun. 11:2781. PubMed
  39. Parriott G, et al. 2020. Immunology. 160:280. PubMed
  40. Phiwpan K, et al. 2015. PLoS One. 10:128198. PubMed
  41. Ma X et al. 2019. Cell Metab. 30(1):143-156 . PubMed
  42. Yu Y, et al. 2022. Nat Commun. 13:6357. PubMed
  43. Luo Y et al. 2019. Cell reports. 26(7):1869-1879 . PubMed
  44. Deng B, et al. 2022. J Immunother Cancer. 10:. PubMed
  45. Chen L, et al. 2021. Cell Death Differ. 28:1880. PubMed
  46. Qi T, et al. 2020. Cell Rep. 33:108452. PubMed
  47. Ruer-Laventie J, et al. 2020. Bio Protoc. e3531:10. PubMed
  48. Sinclair LV et al. 2019. Elife. 8 pii: e44210. PubMed
  49. Yue X, et al. 2019. Nat Commun. 10:2011. PubMed
  50. Lu Y, et al. 2021. Gastroenterology. 161:575. PubMed
  51. Kondratieva T, et al. 2020. PLoS One. 15:e0239668. PubMed
  52. Chin AL, et al. 2021. Nat Commun. 12:5138. PubMed
  53. Darragh LB, et al. 2022. Nat Commun. 13:7015. PubMed
  54. Glassman CR, et al. 2021. eLife. 10:00. PubMed
  55. Fu X, et al. 2020. Aging (Albany NY). 12:15656. PubMed
  56. Yang W, et al. 2020. Methods Mol Biol. 2111:91. PubMed
  57. Luo J, et al. 2022. J Nanobiotechnology. 20:228. PubMed
  58. Kulkarni R, et al. 2021. PLoS One. 16:e0257191. PubMed
  59. Coquery C, et al. 2014. PLoS One. 9:102284. PubMed
  60. Cowan J, et al. 2014. J Immunol. 193:1204. PubMed
  61. White C, et al. 2015. J Immunol. 194:697. PubMed
  62. Faust HJ, et al. 2020. J Clin Invest. 130:5493. PubMed
  63. Vaena S, et al. 2021. Cell Reports. 35(5):109076. PubMed
  64. Su X, et al. 2022. J Transl Med. 20:378. PubMed
  65. Covarrubias AJ, et al. 2020. Nat Metab. 1265:2. PubMed
  66. Morimoto Y, et al. 2018. Immunity. 49:134. PubMed
  67. Biton M et al. 2018. Cell. 175(5):1307-1320 . PubMed
  68. Frost JN, et al. 2021. Med (N Y). 2:164. PubMed
  69. Borges da Silva H, et al. 2020. Immunity. 53(1):158-171.e6. PubMed
  70. Yang BH, et al. 2020. Cell Reports. 27(12):3629-3645.e6.. PubMed
  71. Kretschmer L, et al. 2020. Nat Commun. 0.536805556. PubMed
  72. Ma K, et al. 2022. iScience. 25:104347. PubMed
  73. Matsumura T, et al. 2022. Nat Commun. 13:7064. PubMed
  74. Wang Y, et al. 2021. Nat Commun. 12:4964. PubMed
  75. Jenkinson W, et al. 2012. PLoS One. 7:e53416. PubMed
  76. Daneshmandi S, et al. 2021. Cell Reports. 34(10):108831. PubMed
  77. Liu YG, et al. 2019. FASEB J. 33:5018. PubMed
  78. Resch TK, et al. 2018. Sci Rep. 0.722916667. PubMed
  79. Roy S, et al. 2021. Nat Commun. 12:3182. PubMed
  80. Do-Thi VA, et al. 2021. Cancers (Basel). 13:. PubMed
  81. Asadi Shahmirzadi A, et al. 2020. Cell Metabolism. 32(3):447-456.e6. PubMed
  82. Amezcua Vesely MC, et al. 2020. Cell. 178(5):1176-1188.e15.. PubMed
  83. Fan MY et al. 2018. Cell reports. 25(5):1204-1213 . PubMed
  84. Schaffert S, et al. 2015. J Immunol. 195: 1470-1479. PubMed
  85. Hoechst B, et al. 2016. J Immunol. 195:1517-1523. PubMed
  86. Xu Y, et al. 2016. Nat Commun. 7:12073. PubMed
  87. Webb LM, et al. 2020. J Clin Invest. 130:1683. PubMed
  88. Shimba A et al. 2018. Immunity. 48(2):286-298 . PubMed
  89. Yoshida H, et al. 2019. Cell. 176:897. PubMed
  90. Kim S, et al. 2022. Cancers (Basel). 14:. PubMed
  91. Wagner AK, et al. 2022. iScience. 25:105137. PubMed
  92. Fedele C, et al. 2021. J Exp Med. 218: . PubMed
  93. Kooijman S, et al. 2015. Am J Physiol Heart Circ Physiol. 309: H646-H654. PubMed
  94. Lin JD, et al. 2020. Cell Host & Microbe. 27(5):830-840. PubMed
  95. Chakraborty P, et al. 2020. Cell Reports. 28(7):1879-1893.e7.. PubMed
  96. Parks CA, et al. 2019. Proc Natl Acad Sci U S A. 116:3136. PubMed
  97. Yue T, et al. 2022. Cell Death Differ. 29:218. PubMed
  98. Rochford I, et al. 2021. Am J Physiol Lung Cell Mol Physiol. 321:L686. PubMed
  99. Liu X, et al. 2021. Adv Sci (Weinh). 8:e2100233. PubMed
  100. Angela M, et al. 2016. Nat Commun. 7:13683. PubMed
  101. Katsuyama T, et al. 2021. Cell Reports. 36(1):109339. PubMed
  102. Timilshina M, et al. 2020. Cell Reports. 27(10):2948-2961.e7.. PubMed
  103. Bae S, et al. 2021. Cell Reports. 35(11):109264. PubMed
  104. Louise V Webb et al. 2019. Immunity. 50(2):348-361 . PubMed
  105. Chen S, et al. 2018. Nat Commun. 9:5298. PubMed
  106. Hodgson R, et al. 2022. Commun Biol. 5:1216. PubMed
  107. Jiang W, et al. 2021. Cell Rep. 37:110112. PubMed
  108. Chang MH, et al. 2021. Cell Rep. 37:109902. PubMed
  109. Yu Z, et al. 2021. Biomed Res Int. 2021:9958745. PubMed
RRID
AB_313098 (BioLegend Cat. No. 104411)
AB_313099 (BioLegend Cat. No. 104412)

Antigen Details

Structure
Selectin, 95 kD (neutrophils) or 74 kD (lymphocytes)
Distribution

Subsets of B and T cells, monocytes, granulocytes, subset of NK cells

Function
Lymphocyte homing to HEV, rolling on activated endothelium
Ligand/Receptor
CD34, GlyCAM-1, MAdCAM-1
Cell Type
B cells, Granulocytes, Monocytes, Neutrophils, NK cells, T cells, Tregs
Biology Area
Cell Adhesion, Cell Biology, Costimulatory Molecules, Immunology, Innate Immunity
Molecular Family
Adhesion Molecules, CD Molecules
Antigen References

1. Barclay AN, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Kishimoto TK, et al. 1990. P. Natl. Acad. Sci. USA 87:2244.
3. Tedder TF, et al. 1995. J. Exp. Med. 181:2259.

Gene ID
20343 View all products for this Gene ID
UniProt
View information about CD62L on UniProt.org

Related FAQs

There are no FAQs for this product.
Go To Top Version: 1    Revision Date: 11/30/2012

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account